Illumina Inc (ILMN : NASDAQ)
Common Stock
$288.79
USD
+9.32 (3.33%)
Last updated: 2026-10-28
Follow ILMN
ILMN
Illumina Inc
WealthAwesomePerformance
1 Day
+3.33%
1 Week
+2.10%
1 Month
+6.21%
YTD
+114.95%
Key Statistics
Market Cap
$43.61B
52W High
$309.35
52W Low
$106.12
P/E Ratio
53.88
50 Day MA
$247.14
200 Day MA
$174.93
Beta
1.42
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $278.04 | $294.20 | $277.20 | $288.79 | $288.79 | 2,227,096 |
| 10/27/2026 | $269.42 | $282.18 | $266.20 | $279.47 | $279.47 | 1,774,648 |
| 10/26/2026 | $269.69 | $274.00 | $267.29 | $271.04 | $271.04 | 1,276,602 |
| 10/23/2026 | $264.42 | $271.64 | $264.42 | $269.42 | $269.42 | 1,262,800 |
| 10/22/2026 | $281.42 | $283.55 | $257.31 | $269.40 | $269.40 | 2,224,145 |
| 10/21/2026 | $267.35 | $286.40 | $263.28 | $282.86 | $282.86 | 2,216,241 |
| 10/20/2026 | $264.13 | $271.43 | $260.15 | $267.93 | $267.93 | 1,584,120 |
| 10/19/2026 | $268.93 | $270.94 | $260.24 | $262.66 | $262.66 | 1,901,854 |
| 10/16/2026 | $267.49 | $272.01 | $259.26 | $262.54 | $262.54 | 2,489,000 |
| 10/15/2026 | $267.24 | $275.49 | $257.14 | $267.93 | $267.93 | 2,989,000 |
Analyst Price Targets
Based on 21 analysts covering ILMN · as of Oct 26, 2026
Wall Street analysts forecast ILMN stock price to fall 13.8% over the next 12 months.
Consensus
Buy3.57 / 5.00
Avg. Target
US$248.90
-13.8% Upside
Previously US$245.80 on Oct 20, 2026
Current Price
US$288.79
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ILMN's historical volatility
30-Day Vol
55.0%
Annualized
90-Day Vol
48.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$345.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$306.50 | US$253.54 – US$370.53 |
| 60 trading days | US$325.30 | US$248.75 – US$425.41 |
| 90 trading days | US$345.25 | US$248.56 – US$479.56 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $4.49B
- EBITDA
- $1.16B
- Profit Margin
- 18.34%
- ROE (TTM)
- 32.34%
- EPS (Diluted)
- 5.36
- Book Value
- 18.80
Classification
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ILMN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| ATYR | aTyr Pharma, Inc. | $5.14 | +4041.94% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| KPTI | Karyopharm Therapeutics Inc | $0.83 | +73.35% |
ILMN.US news timeline
7 articles covering ILMN.US, most recent first
Latest